Latest News - Page 2 of 41 - Oklahoma Society of Clinical Oncology

INREBIC® (fedratinib) capsules, a product from Celgene, is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INDICATION INREBIC® (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). IMPORTANT SAFETY […]

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Merck announces new FDA approval for KEYTRUDA Merck is pleased to announce that KEYTRUDA, in combination with axitinib, has been approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC). PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients FDA=Food and Drug Administration; PD-L1=programmed […]

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS). Effective for dates of services on or after January 1, 2019, J-Code J9173 can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in the […]

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and […]

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS). Effective for dates of services on or after January 1, 2019, the following code can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in […]

Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.1 An estimated 37% of AML patients have a FLT3 mutation and […]

On November 16, 2018, the U.S. Food and Drug Administration (FDA) approved a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use. The new indication is as follows: Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not […]